NcXHF

MANAGING IMMUNE CHECKPOINT-BLOCKING ANTIBODY SIDE EFFECTS
cells via augmented ERK signaling mediated by a RAF inhibitor. Cancer
Immunol Res. 2014;2:70-79.
64. Boni A, Cogdill AP, Dang P, et al. Selective BRAFV600E inhibition enhances
T-cell recognition of melanoma without affecting lymphocyte
function. Cancer Res. 2010;70:5213-5219. Epub 2010 Jun 15.
65. Sapkota B, Hill CE, Pollack BP. Vemurafenib enhances MHC induction
in BRAFV600E homozygous melanoma cells. Oncoimmunology. 2013;
2:e22890.
66. Frederick DT, Piris A, Cogdill AP, et al. BRAF inhibition is associated
with enhanced melanoma antigen expression and a more favorable tumor
microenvironment in patients with metastatic melanoma. Clin
Cancer Res. 2013;19:1225-1231.
67. Sumimoto H, Imabayashi F, Iwata T, et al. The BRAF-MAPK signaling
pathway is essential for cancer-immune evasion in human melanoma
cells. J Exp Med. 2006;203:1651-1656.
68. Comin-Anduix B, Chodon T, Sazegar H, et al. The oncogenic BRAF
kinase inhibitor PLX4032/RG7204 does not affect the viability or function
of human lymphocytes across a wide range of concentrations. Clin
Cancer Res. 2010;16:6040-6048.
69. Ribas A, Hodi FS, Callahan M, et al. Hepatotoxicity with combination of
vemurafenib and ipilimumab. N Engl J Med. 2013;368:1365-1366.
70. Harding JJ, Pulitzer M, Chapman PB. Vemurafenib sensitivity skin reaction
after ipilimumab. N Engl J Med. 2012;366:866-868.
71. Puzanov I, Callahan MK, Linette GP, et al. Phase 1 study of the BRAF
inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib
(T) in combination with ipilimumab (Ipi) for V600E/K mutationpositive
unresectable or metastatic melanoma (MM). J Clin Oncol. 2014;
32:5s (suppl; abstr 2511).
72. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of
B16 melanoma using anticytotoxic T lymphocyte-associated antigen 4
(CTLA-4) and granulocyte/macrophage colony-stimulating factor
(GM-CSF)-producing vaccines induces rejection of subcutaneous and
metastatic tumors accompanied by autoimmune depigmentation. J Exp
Med. 1999;190:355-366.
73. Hodi FS, Lee S, McDermott DF, et al. Ipilimumab plus sargramostim vs.
ipilimumab alone for treatment of metastatic melanoma: a randomized
clinical trial. JAMA. 2014;312:1744-1753.
74. Goldstein JI, Kominsky DJ, Jacobson N, et al. Defective leukocyte GM-
CSF receptor (CD116) expression and function in inflammatory bowel
disease. Gastroenterology. 2011;141:208-216.
75. Kyi C, Hellmann MD, Wolchok JD, et al. Opportunistic infections in
patients treated with immunotherapy for cancer. J Immunother Cancer.
2014;2:19.
76. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with
tumor regression in patients with metastatic melanoma treated with
anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005;23:6043-
6053.
77. Downey SG, Klapper JA, Smith FO, et al. Prognostic factors related to
clinical response in patients with metastatic melanoma treated by CTLassociated
antigen-4 blockade. Clin Cancer Res. 2007;13:6681-6688.
Epub 2007 Nov 2.
78. Wang HB, Shi FD, Li H, et al. Anti-CTLA-4 antibody treatment triggers
determinant spreading and enhances murine myasthenia gravis. J Immunol.
2001;166:6430-6436.
79. Lühder F, Höglund P, Allison JP, et al. Cytotoxic T lymphocyteassociated
antigen 4 (CTLA-4) regulates the unfolding of autoimmune
diabetes. J Exp Med. 1998;187:427-432.
80. Kyi C, Carvajal RD, Wolchok JD, et al. Ipilimumab in patients with
melanoma and autoimmune disease. J Immunother Cancer. 2014;
2:35.
81. Pedersen M, Andersen R, Nørgaard P, et al. Successful treatment with
ipilimumab and interleukin-2 in two patients with metastatic melanoma
and systemic autoimmune disease. Cancer Immunol Immunother.
2014;63:1341-1346.
82. Gettings EJ, Hackett CT, Scott TF. Severe relapse in a multiple sclerosis
patient associated with ipilimumab treatment of melanoma. Mult Scler.
Epub 2014 Sep 25.
asco.org/edbook | 2015 ASCO EDUCATIONAL BOOK 83